ElevateBio

OverviewSuggest Edit

ElevateBio is a company focused on creating and operating a portfolio of cell and gene therapy companies to develop, manufacture and commercialize life-transforming medicines. The company is building a facility that is intended to manufacture experimental gene and cell therapies for multiple startups, and aims to invest in those companies and help them grow.  ElevateBio provides its portfolio companies with basic and translational research, process development, cGMP manufacturing, clinical development, regulatory affairs, and commercial operations.

TypePrivate
Founded2017
HQCambridge, US
Websiteelevate.bio

Latest Updates

Employees (est.) (Mar 2020)60(+18%)

ElevateBio Office Locations

ElevateBio has an office in Cambridge
Cambridge, US (HQ)
139 Main St Suite 500
Show all (1)

ElevateBio Financials and Metrics

Summary Metrics

Founding Date

2017

ElevateBio total Funding

$320 m

ElevateBio latest funding size

$170 m

Time since last funding

2 days ago

ElevateBio investors

ElevateBio's latest funding round in March 2020 was reported to be $170 m. In total, ElevateBio has raised $320 m
Show all financial metrics

ElevateBio Online and Social Media Presence

Embed Graph

ElevateBio News and Updates

Cell and gene therapy startup ElevateBio raises $170 million

While economic conditions and the ongoing global coronavirus pandemic may not make for the best atmosphere for raising funding, some companies are still announcing round closures with significant money committed. Cambridge-based ElevateBio, for instance, revealed a $170 million Series B funding on M…

ElevateBio Blogs

AlloVir Expands Its Research Collaboration with Baylor College of Medicine to Discover and Develop Allogeneic, Off-the-Shelf, Virus-Specific T-Cell Therapies for COVID-19 (Copy)

AlloVir, a late-clinical stage allogeneic T-cell immunotherapy company, today announced it has been granted Orphan Drug Designation from the European Medicines Agency (EMA) for Viralym-M (ALVR105) as a potential treatment of viral diseases and infections in patients undergoing hematopoietic stem…

ElevateBio Appoints Kareem Reda as Chief Business Officer

ElevateBio, a Cambridge-based cell and gene therapy holding company, today announced that Kareem Reda has been appointed to the newly created position of Chief Business Officer. Mr. Reda has a strong track record of leading strategic acquisitions, business deals and financing efforts, and experi…

AlloVir to Present at the SVB Leerink 9th Annual Global Healthcare Conference

AlloVir, a late-clinical stage T-cell immunotherapy company, today announced that its Chief Executive Officer, David Hallal will present at the 9th annual SVB Leerink Global Healthcare Conference on Tuesday February 25th at 2:00 PM ET at the Lotte New York Palace in New York City. AlloVir, an El…

AlloVir Receives the European Medicines Agency PRIME Designation for Viralym-M

AlloVir, a late-clinical stage T-cell immunotherapy company, today announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to Viralym-M (ALVR105), the company’s lead allogeneic, off-the-shelf, multi-virus specific T-cell therapy, for the treatment of…

ElevateBio Appoints Melissa K. Carpenter, Ph.D., as Chief Scientific Officer of Regenerative Medicine

ElevateBio, a Cambridge-based cell and gene therapy holding company, today announced that Melissa K. Carpenter, Ph.D., has been appointed to the newly created position of Chief Scientific Officer of Regenerative Medicine. Dr. Carpenter will be responsible for expanding ElevateBio’s portfolio of …

ElevateBio Launches HighPassBio to Advance Novel Targeted T Cell Immunotherapies with Technology from Fred Hutchinson Cancer Research

ElevateBio, a Cambridge-based biotechnology holding company, today announced it has established and launched HighPassBio, a company dedicated to advancing novel targeted T cell immunotherapies. The company’s lead product is an engineered T cell receptor (TCR) T cell therapy for HA-1 expressing t…
Show more

ElevateBio Frequently Asked Questions

  • When was ElevateBio founded?

    ElevateBio was founded in 2017.

  • How many employees does ElevateBio have?

    ElevateBio has 60 employees.

  • Who are ElevateBio competitors?

    Competitors of ElevateBio include TransCure bioServices, Chrometec Capital and Start Codon.

  • Where is ElevateBio headquarters?

    ElevateBio headquarters is located at 139 Main St Suite 500, Cambridge.

  • Where are ElevateBio offices?

    ElevateBio has an office in Cambridge.

  • How many offices does ElevateBio have?

    ElevateBio has 1 office.